Enveric Biosciences Hires Fish & Richardson to Defend Patent Tied to AbbVie Deal [Investing.com]
Wednesday, October 15, 2025 1 min read
Key Takeaway: Enveric Biosciences has engaged Fish and Richardson P.C. to defend against a Post-Grant Review petition from Gilgamesh Pharmaceuticals. This petition arises following Gilgamesh's agreement to be acquired by AbbVie for up to $1.2 billion. The move underscores Enveric's commitment to protecting its intellectual property.
Price reaction · baseline $8.6856 (2025-10-14 close) · hit pre-market · 4 other ENVB headline(s) in the window, move may be shared
day 0 close · peak
+24.4%
day 1
+8.9%
day 3
-1.5%
Market Sentiment Analysis
POSITIVE FACTORS
Enveric Biosciences is actively defending its intellectual property.
The involvement of a prominent law firm indicates a strong legal strategy.
The acquisition of Gilgamesh Pharmaceuticals by AbbVie highlights the value of the assets.
Full Press Release Details
Enveric Biosciences (NASDAQ: ENVB) has hired prominent intellectual property law firm Fish and Richardson P.C. to contest a Post-Grant Review (PGR) petition filed by Gilgamesh Pharmaceuticals, which earlier this year agreed to be acquired by AbbVie for up to $1.2 billion, Investing.com has learned.
Full Article >>
Frequently Asked Questions
Who has Enveric Biosciences hired for legal defense?
Enveric Biosciences has hired Fish and Richardson P.C. for legal defense.
What is the reason for Enveric's legal action?
The legal action is in response to a Post-Grant Review petition from Gilgamesh Pharmaceuticals.
What deal is associated with Gilgamesh Pharmaceuticals?
Gilgamesh Pharmaceuticals has agreed to be acquired by AbbVie for up to $1.2 billion.
What does a Post-Grant Review petition involve?
A Post-Grant Review petition challenges the validity of a patent after it has been granted.